Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy

Summary

This early phase 1 trial studies the use of everolimus in restoring salivary gland function in participants with locally advanced head and neck cancer after concurrent chemoradiation or radiation therapy alone.

Timeline

Start

2018-05-04

Primary completion

2019-11-15

Completion

2019-11-15

Outcome

Outcome not reported

Stopped: “UACC-PHX is no longer able to support the study and Novartis is unable to provide drug beyond December 2019.”

Drugs

Indications